1000 Participants Needed

Genetic Study for Juvenile Myoclonic Epilepsy

(BIOJUME Trial)

Recruiting at 13 trial locations
AC
AH
DK
Overseen ByDeb K Pal, MD PhD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to uncover the genetic cause of Juvenile Myoclonic Epilepsy (JME), potentially leading to better treatments and early detection. Researchers collect blood samples from individuals diagnosed with JME and compare them to those without seizures. This comparison helps identify genetic differences that might cause JME. Candidates may be suitable if they have JME with seizures beginning between ages 10 and 25, especially if frequent morning muscle jerks occur.

As an unphased study, this trial offers a unique opportunity to contribute to groundbreaking research that could transform future JME treatments and early detection methods.

Do I need to stop my current medications to join the trial?

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Why are researchers excited about this trial?

Researchers are excited about this trial because it aims to uncover the biological factors behind juvenile myoclonic epilepsy (JME) by analyzing blood samples. Unlike traditional treatments that focus on managing symptoms with medications like valproic acid or lamotrigine, this research could pave the way for more targeted therapies by understanding the condition at a deeper biological level. By comparing blood samples from those with JME and those without seizures, scientists hope to identify unique biomarkers, potentially leading to more personalized and effective treatments in the future.

Who Is on the Research Team?

KP

K Pal, MD PhD

Principal Investigator

King's College London

Are You a Good Fit for This Trial?

Inclusion Criteria

Diagnosis of Juvenile Myoclonic Epilepsy in accordance with Consensus criteria
Age of myoclonus onset 10-25 years
Seizures comprising predominant or exclusive early morning myoclonus of upper extremities
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Data Collection

Participants provide a blood sample and clinical data, including EEG, for genetic analysis

1 day
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after data collection

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Blood draw

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Group I: Patients diagnosed with JMEExperimental Treatment1 Intervention
Group II: ControlsExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

King's College London

Lead Sponsor

Trials
772
Recruited
26,130,000+

King's College Hospital NHS Trust

Collaborator

Trials
267
Recruited
505,000+

Charles University, Czech Republic

Collaborator

Trials
248
Recruited
8,417,000+

The Hospital for Sick Children

Collaborator

Trials
724
Recruited
6,969,000+

Cardiff University

Collaborator

Trials
102
Recruited
1,035,000+

Odense University Hospital

Collaborator

Trials
808
Recruited
1,272,000+

Hopital Universitaire Robert-Debre

Collaborator

Trials
23
Recruited
23,900+

Vestre Viken Hospital Trust

Collaborator

Trials
107
Recruited
137,000+